The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study
Open accessAbstract
Purpose: To determine whether the addition of paclitaxel to doxorubicin plus cisplatin improves overall survival (OS) in women with advanced or recurrent endometrial carcinoma. Secondary comparisons included progression-free survival (PFS), response rate (RR), and toxicities. Patients and Methods: Eligible, consenting patients received doxorubicin 60 mg/m 2 and cisplatin 50 mg/m 2 (AP), or doxorubicin 45 mg/m 2 and cisplatin 50 mg/m 2 (day 1), followed by paclitaxel 160 mg/m 2 (day 2) with filgrastim support (TAP). The initial doxorubicin dose in the AP arm was reduced to 45 mg/m 2 in patients with prior pelvic radiotherapy and those older than 65 years. Both regimens were repeated every 3 weeks to a maximum of seven cycles. Patients completed a neurotoxicity questionnaire before each cycle. Results: Two hundred seventy-three women (10 ineligible) were registered. Objective response (57% v 34%; P < .01), PFS (median, 8.3 v 5.3 months; P < .01), and OS (median, 15.3 v 12.3 months; P = .037) were improved with TAP. Treatment was hematologically well tolerated, with only 2% of patients receiving AP, and 3% of patients receiving TAP experiencing neutropenic fever. Neurologic toxicity was worse for those receiving TAP, with 12% grade 3, and 27% grade 2 peripheral neuropathy, compared with 1% and 4%, respectively, in those receiving AP. Patient-reported neurotoxicity was significantly higher in the TAP arm following two cycles of therapy. Conclusion: TAP significantly improves RR, PFS, and OS compared with AP. Evaluation of this regimen in the high-risk adjuvant setting is warranted, but close attention should be paid to the increased risk of peripheral neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Rectangular Confidence Regions for the Means of Multivariate Normal Distributions
Šidák, Z. (1967) · Journal of the American Statistical Association · doi:10.1080/01621459.1967.10482935 · Cited by 2,639
Plackett, R. L., & Cox, D. R. (1971) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344247 · Cited by 2,264
Sample-Size Formula for the Proportional-Hazards Regression Model
Schoenfeld, D. A. (1983) · Biometrics · doi:10.2307/2531021 · Cited by 1,096
Cella, D., Hahn, E. A., & Dineen, K. (2002) · Quality of Life Research · doi:10.1023/a:1015276414526 · Cited by 523
Self-citationThigpen, J. T., Brady, M. F., Alvarez, R. D., Adelson, M. D., Homesley, H. D., Manetta, A., Soper, J. T., & Given, F. T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1736 · Cited by 484
Computing an Exact Confidence Interval for the Common Odds Ratio in Several 2×2 Contingency Tables
Mehta, C. R., Patel, N. R., & Gray, R. (1985) · Journal of the American Statistical Association · doi:10.1080/01621459.1985.10478212 · Cited by 328
Cited by
Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., & Vergote, I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67063-8 · Cited by 1,497
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv484 · Cited by 1,386
Aapro, M. S., Bohlius, J., Cameron, D. A., Lago, L. D., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.013 · Cited by 1,090
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., Gonzalez-Martin, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000609 · Cited by 767
Current recommendations and recent progress in endometrial cancer
Brooks, R. A., Fleming, G. F., Lastra, R. R., Lee, N. K., Moroney, J. W., Son, C. H., Tatebe, K., & Veneris, J. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21561 · Cited by 573
Self-citationChemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Abu-Rustum, N., Yashar, C., Arend, R., Barber, E., Bradley, K., Brooks, R., Campos, S. M., Chino, J., Chon, H. S., Chu, C., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0006 · Cited by 568
Aapro, M. S., Cameron, D. A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Kearney, N., Lyman, G. H., Tjan-Heijnen, V. C., Walewski, J., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.002 · Cited by 539
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
Matei, D., Filiaci, V., Randall, M. E., Mutch, D., Steinhoff, M. M., DiSilvestro, P. A., Moxley, K. M., Kim, Y. M., Powell, M. A., O’Malley, D. M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813181 · Cited by 477
Endometrial cancer: A review and current management strategies: Part II
Burke, W. M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A. B., Brewer, M., Boruta, D., Herzog, T. J., & Shahin, F. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.06.003 · Cited by 459
Susumu, N., Sagae, S., Udagawa, Y., Niwa, K., Kuramoto, H., Satoh, S., & Kudo, R. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.09.029 · Cited by 445
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Thigpen, J. T., Brady, M. F., Homesley, H. D., Malfetano, J., DuBeshter, B., Burger, R. A., & Liao, S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.088 · Cited by 390
Self-citationAmant, F., Mirza, M. R., Koskas, M., & Creutzberg, C. L. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12612 · Cited by 356
Miller, D. S., Filiaci, V. L., Mannel, R. S., Cohn, D. E., Matsumoto, T., Tewari, K. S., DiSilvestro, P., Pearl, M. L., Argenta, P. A., Powell, M. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01076 · Cited by 351
Self-citationOza, A. M., Elit, L., Tsao, M.-S., Kamel-Reid, S., Biagi, J., Provencher, D. M., Gotlieb, W. H., Hoskins, P. J., Ghatage, P., Tonkin, K. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1578 · Cited by 341
Sorosky, J. I. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3182605bf1 · Cited by 332
Aghajanian, C., Sill, M. W., Darcy, K. M., Greer, B., McMeekin, D. S., Rose, P. G., Rotmensch, J., Barnes, M. N., Hanjani, P., & Leslie, K. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6397 · Cited by 326
Amant, F., Mirza, M. R., & Creutzberg, C. L. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60024-1 · Cited by 309
Cancer of the corpus uteri: 2021 update
Koskas, M., Amant, F., Mirza, M. R., & Creutzberg, C. L. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13866 · Cited by 298
Contemporary management of endometrial cancer
Wright, J. D., Medel, N. I. B., Sehouli, J., Fujiwara, K., & Herzog, T. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60442-5 · Cited by 270
Boruta, D. M., Gehrig, P. A., Fader, A. N., & Olawaiye, A. B. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.06.011 · Cited by 254
Management of women with clear cell endometrial cancer
Olawaiye, A. B., & Boruta, D. M. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.02.003 · Cited by 124
Barber, E. L., Chen, S., Pineda, M. J., Robertson, S. E., Hill, E. K., Teoh, D., Schilder, J., O'Shea, K. L., Kocherginsky, M., Zhang, B., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0147 · Cited by 9
Metadata
- Authors
- Fleming, G. F., Brunetto, V. L., Cella, D., Look, K. Y., Reid, G. C., Munkarah, A. R., Kline, R., Burger, R. A., Goodman, A., & Burks, R. T.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-06-01
- Volume
- 22
- Issue
- 11
- Pages
- 2159-2166
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2169183724
- Cited by
- 565
- References
- 19
- FWCI
- 34.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.